# OnCo record braf-v600e-nsclc (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/braf-v600e-nsclc/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "braf-v600e-nsclc" ;
  schema:name "BRAF V600E-mutant non-small-cell lung cancer"@en ;
  schema:alternateName "BRAF-mutant lung cancer"@en, "BRAF V600E NSCLC"@en, "BRAF V600-mutated lung adenocarcinoma"@en ;
  schema:description "BRAF V600E lung cancer carries the same mutation as many melanomas and is treated with the same pairs of pills that block BRAF and MEK together. Dabrafenib with trametinib and encorafenib with binimetinib each shrink about two thirds to three quarters of untreated tumours."@en ;
  schema:url <https://onco.cc/cancers/braf-v600e-nsclc/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/BRAF_(gene)> ;
  schema:citation <https://en.wikipedia.org/wiki/BRAF_(gene)>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450> ;
  onco:tag "subtype-page", "lung" ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cgp/> ;
  onco:targets <https://onco.cc/targets/braf/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/dabrafenib/>, <https://onco.cc/drugs/trametinib/>, <https://onco.cc/drugs/encorafenib/>, <https://onco.cc/drugs/binimetinib/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/pfizer/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/nsclc-signalling/> ;
  onco:terms <https://onco.cc/terms/braf-v600-mutation/>, <https://onco.cc/terms/driver-mutation/>, <https://onco.cc/terms/resistance/>, <https://onco.cc/terms/tps/> ;
  onco:trials <https://onco.cc/trials/pharos/> ;
  onco:people <https://onco.cc/people/david-planchard/> ;
  onco:pipeline <https://onco.cc/trials/pharos/>, <https://onco.cc/drugs/encorafenib/>, <https://onco.cc/drugs/binimetinib/> ;
  onco:standardOfCare <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/dabrafenib/>, <https://onco.cc/drugs/trametinib/>, <https://onco.cc/drugs/encorafenib/>, <https://onco.cc/drugs/binimetinib/>, <https://onco.cc/trials/pharos/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/terms/braf-v600-mutation/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/encorafenib/>, <https://onco.cc/drugs/binimetinib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/trametinib/> .